Table 5.
Summary of previous published articles regarding steroid effect in acute tubulointerstitial nephritis
| Study | Case no. | Etiology | Steroid use (%) | Outcome analysis | Results |
|---|---|---|---|---|---|
| Prendecki, 2017 | 187 | All etiologiesa | 84 | Median eGFR comparison at 1, 3, 6, 12, 24 months, and last follow-up | The steroid-treated group had a significantly higher eGFR at 6, 12, 24 months and at last follow-up |
| Valluri, 2015 | 124 | Drug induced | 59 | Median sCr comparison and renal recovery within 1 year (complete: return to baseline sCr) | No difference in sCr at time points of 1, 6, and 12 months and no difference in renal recovery between the two groups (48% vs. 41%) |
| Muriithi, 2014 | 95 | Drug induced | 87 | Renal recovery at 6 months (complete: within 25% of its baseline or < 1 .4mg/dL if baseline was not available, partial: ≥50% decrease of peak sCr) | Treatment with steroids did not affect renal recovery status at 6 months (complete: partial: none = 49%: 39%: 12% vs. 17%: 67%: 16%; P = 0.3) |
| Raza, 2012 | 49 | All etiologiesb | 76 | Fold improvement in eGFR at last follow-up | Greater improvement in eGFR in patients with steroids (3.4 vs. 2.1; P < 0.05) |
| Gonzalez, 2008 | 61 | Drug induced | 85 | Median sCr comparison and renal recovery (> 50% decrease of peak sCr) based on last follow-up | Significantly lower sCr in steroid group (2.1 vs. 3.7, P < 0.05), No significant change in renal recovery between two groups (54% vs. 33%, P = ns) |
| Clarkson, 2004 | 42 | All etiologiesc | 62 | Median sCr comparison at 1, 6, and 12 months | No difference in sCr at time points of 1, 6, and 12 months between the two groups |
| Yun, 2018 | 102 | Idiopathic & drug induced | 80 | Renal recovery at 6 months (≥50% decrease of peak sCr or < 1 .3mg/dL) | Treatment with steroids did not affect renal recovery at 6 months (67.1% vs. 50.0%, P = 0.154) |
eGFR, estimated glomerular filtration rate, sCr, serum creatinine, ns not significant
aIdiopathic/others (48%), drug induced (25%), tuberculosis (13%), sarcoidosis (9%), tubulointerstitial nephritis and uveitis (3%), and Sjögren syndrome (2%)
bDrug induced (67%), idiopathic (20%), tubulointerstitial nephritis and uveitis (8%), and sarcoidosis (4%)
cDrug induced, idiopathic, tubulointerstitial nephritis and uveitis, and others; but proportions were not described